Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Teklab, Gebregiworgis"'
Autor:
Teklab Gebregiworgis, Jonathan Yui-Lai Chan, Douglas A. Kuntz, Gilbert G. Privé, Christopher B. Marshall, Mitsuhiko Ikura
Publikováno v:
European Journal of Cell Biology, Vol 103, Iss 2, Pp 151414- (2024)
The RAS isoforms (KRAS, HRAS and NRAS) have distinct cancer type-specific profiles. NRAS mutations are the second most prevalent RAS mutations in skin and hematological malignancies. Although RAS proteins were considered undruggable for decades, isof
Externí odkaz:
https://doaj.org/article/3a8df14dd4c348f6b90cd509a98b511e
Autor:
Teklab Gebregiworgis, Yoshihito Kano, Jonathan St-Germain, Nikolina Radulovich, Molly L. Udaskin, Ahmet Mentes, Richard Huang, Betty P. K. Poon, Wenguang He, Ivette Valencia-Sama, Claire M. Robinson, Melissa Huestis, Jinmin Miao, Jen Jen Yeh, Zhong-Yin Zhang, Meredith S. Irwin, Jeffrey E. Lee, Ming-Sound Tsao, Brian Raught, Christopher B. Marshall, Michael Ohh, Mitsuhiko Ikura
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
SHP2 promotes RAS-driven MAPK signalling, but it is unclear why cancer cells with distinct KRAS mutations exhibit differential sensitivity to SHP2 inhibition. Here the authors show that KRAS Q61H is decoupled from SHP2- mediated upstream regulation,
Externí odkaz:
https://doaj.org/article/adc5eaa39af340409424aef1fcf1144b
Autor:
Yoshihito Kano, Teklab Gebregiworgis, Christopher B. Marshall, Nikolina Radulovich, Betty P. K. Poon, Jonathan St-Germain, Jonathan D. Cook, Ivette Valencia-Sama, Benjamin M. M. Grant, Silvia Gabriela Herrera, Jinmin Miao, Brian Raught, Meredith S. Irwin, Jeffrey E. Lee, Jen Jen Yeh, Zhong-Yin Zhang, Ming-Sound Tsao, Mitsuhiko Ikura, Michael Ohh
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
Deregulation of the RAS GTPase cycle due to mutations in RAS genes is commonly associated with cancer development. Here authors use NMR and mass spectrometry to shows that KRAS phosphorylation via Src alters the conformation of switch I and II region
Externí odkaz:
https://doaj.org/article/811fdf81e7164853822f6750cc8b6260
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ming Li, Quan Li, Ni Liu, Frances A. Shepherd, Teklab Gebregiworgis, Ming-Sound Tsao, Nadeem Moghal, Nhu-An Pham, Mitsuhiko Ikura, Ningdi Feng Liu, Zhenhao Fang, Hirotsugu Notsuda, Ku-Geng Huo, Christopher B. Marshall
Publikováno v:
Journal of Thoracic Oncology. 17:277-288
Introduction Mutations in BRAF occur in 2-4% of lung adenocarcinoma (LUAD) patients. Combination dabrafenib/trametinib or single-agent vemurafenib is approved only for patients with cancers driven by the V600E BRAF mutation. Targeted therapy is not c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01fccde292ddc9f80ca06196fd41dd14
https://doi.org/10.1016/j.jtho.2021.09.008
https://doi.org/10.1016/j.jtho.2021.09.008
Autor:
Mitsuhiko Ikura, Teklab Gebregiworgis, Christopher B. Marshall, Ki-Young Lee, Geneviève M.C. Gasmi-Seabrook, Masahiro Enomoto
Publikováno v:
Chemical Science
KRAS forms transient dimers and higher-order multimers (nanoclusters) on the plasma membrane, which drive MAPK signaling and cell proliferation. KRAS is a frequently mutated oncogene, and while it is well known that the most prevalent mutation, G12D,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f17d32a1e8360d61bf6dd8bec0e7f72
https://doi.org/10.1039/d1sc03484g
https://doi.org/10.1039/d1sc03484g
Autor:
Teklab Gebregiworgis, Christopher B. Marshall, Fenneke KleinJan, Geneviève M.C. Gasmi-Seabrook, Ben J Eves, Masahiro Enomoto, Ningdi F Liu, Ki-Young Lee, Mitsuhiko Ikura, Zhenhao Fang
Publikováno v:
Journal of Biomolecular NMR. 74:531-554
Mutations in RAS oncogenes occur in ~ 30% of human cancers, with KRAS being the most frequently altered isoform. RAS proteins comprise a conserved GTPase domain and a C-terminal lipid-modified tail that is unique to each isoform. The GTPase domain is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9fef215478b276d4d293ad38a5ad0b6
https://doi.org/10.1007/s10858-020-00338-6
https://doi.org/10.1007/s10858-020-00338-6
Autor:
KleinJan F, Gasmi-Seabrook Gmc, Kijun Song, Lakhani J, Ezekiel A. Geffken, Christian W. Johnson, Christopher B. Marshall, Teklab Gebregiworgis, Joao A. Paulo, Olesja Popow, Hyuk-Soo Seo, Kevin M. Haigis, Elizabeth M. Terrell, Deborah K. Morrison, Mitsuhiko Ikura, Carla Mattos, Andrew Bo Liu, Sirano Dhe-Paganon
SUMMARYA unifying feature of the RAS superfamily is a functionally conserved GTPase cycle that proteins use to transition between active and inactive states. Here, we demonstrate that active site autophosphorylation of some small GTPases is an intrin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b21a5e25ed3359cf636e46a0147800e9
https://doi.org/10.1101/2021.06.23.449327
https://doi.org/10.1101/2021.06.23.449327
Autor:
Ben J, Eves, Teklab, Gebregiworgis, Geneviève M C, Gasmi-Seabrook, Douglas A, Kuntz, Gilbert G, Privé, Christopher B, Marshall, Mitsuhiko, Ikura
Publikováno v:
Journal of Molecular Biology. 434:167527
Ral Guanine Nucleotide Dissociation Stimulator Like 1 (RGL1) is a RAS effector protein that activates Ral GTPase by stimulating nucleotide exchange. Most structures of RAS-effector complexes are for the HRAS isoform; relatively few KRAS-effector stru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::049303c8369f9b2d22ab65b8f3c7eeca
https://doi.org/10.1016/j.jmb.2022.167527
https://doi.org/10.1016/j.jmb.2022.167527
Autor:
Ku-Geng, Huo, Hirotsugu, Notsuda, Zhenhao, Fang, Ningdi Feng, Liu, Teklab, Gebregiworgis, Quan, Li, Nhu-An, Pham, Ming, Li, Ni, Liu, Frances A, Shepherd, Christopher B, Marshall, Mitsuhiko, Ikura, Nadeem, Moghal, Ming-Sound, Tsao
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 17(2)
Mutations in BRAF occur in 2% to 4% of patients with lung adenocarcinoma. Combination dabrafenib and trametinib, or single-agent vemurafenib is approved only for patients with cancers driven by the V600E BRAF mutation. Targeted therapy is not current
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::90d7b798d67c7b1530d164d38fddda68
https://pubmed.ncbi.nlm.nih.gov/34648945
https://pubmed.ncbi.nlm.nih.gov/34648945